Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: An open trial.

[en] The aim of this open trial was to assess the antidepressant/anxiolytic effects of oxytocin used as an adjunct to antidepressant in treatment-resistant depression. Fourteen patients, who have not responded to 40mg of escitalopram, received intranasal synthetic oxytocin during 4 weeks, in association with antidepressant. This is the first open trial study suggesting OT in association with escitalopram significantly reduced scores on Hamilton Depression Rating Scale.

Disciplines :

Psychiatry

Author, co-author :

Scantamburlo, Gabrielle ; Université de Liège - ULiège > Département des sciences cliniques > Psychiatrie et psychologie médicale

Hansenne, Michel ; Université de Liège - ULiège > Département de Psychologie : cognition et comportement > Psycho. de la personnalité et des différences individuelles

Geenen, Vincent ; Université de Liège - ULiège > Centre d'immunologie

Legros, Jean-Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Ansseau, Marc ; Université de Liège - ULiège > Département des sciences cliniques > Psychiatrie et psychologie médicale

Language :

English

Title :

Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: An open trial.

Publication date :

January 2015

Journal title :

European Psychiatry

ISSN :

0924-9338

eISSN :

1778-3585

Publisher :

Elsevier Masson, Paris, France

Volume :

Issue :

Pages :

65-68

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 30 November 2014

Statistics

Number of views

434 (46 by ULiège)

Number of downloads

622 (26 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Cardoso C., Ellenbogen M., Linnen A. Acute intranasal oxytocin improves positive self-perceptions of personality. Psychopharmacology 2012, 220:741-749.
Domes G., Lischke A., Berger C., Grossmann A., Hauenstein K., Heinrichs M., et al. Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology 2010, 35:83-93.
Ellenbogen M.A., Linnen A.M., Cardoso C., Joober R. Intranasal oxytocin impedes the ability to ignore task-irrelevant facial expressions of sadness in students with depressive symptoms. Psychoneuroendocrinology 2013, 38:387-398.
Endicott J., Nee J., Harrison W., Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993, 29:321-326.
Emiliano A., Cruz T., Pannoni V., et al. The interface of oxytocin-labeled cells and serotonin. Neuropsychopharmacology 2006, 11:1-12.
Forkmann T., Scherer A., Boecker M., et al. The clinical global Impression scale and the influence of patient or staff perspective on outcome. BMC Psychiatry 2011, 11(1):83.
Furman D.J., Chen M.C., Gotlib I.H. Variant in oxytocin receptor gene is associated with amygdala volume. Psychoneuroendocrinology 2011, 36:891-897.
Heinrichs M., Baumgartner T., Kirschbaum C., Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 2003, 54:1389-1398.
Keating C., Dawood T., Barton D., Lambert G., Tilbrook A. Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder. BMC Psychiatry 2013, 29(13):124.
Lischke A., Gamer M., Berger C., Grossmann A., Hauenstein K., Heinrichs M., et al. Oxytocin increases amygdala reactivity to threatening scenes in females. Psychoneuroendocrinology 2012, 37:1431-1438.
Macdonald K., Feifel D. Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. Front Neurosci 2013, 7:1-21.
Mah B.L., Van Ijzendoorn M.H., Smith R., Bakermans-Kranenburg M.J. Oxytocin in postnatally depressed mothers: its influence on mood and expressed emotion. Prog in Neuropsychopharmacol Biol Psychiatr 2013, 40:267-272.
Matsuki M., Matsushita H., Tomizawa K., Matsui H. Oxytocin: a therapeutic target for mental disorder. J Physiol Sci 2012, 62:441-444.
Mendlewicz J., Crisafulli C., Calati R., Kocabas N.A., Massat I., Linotte S., et al. Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. Neurosci Lett 2012, 10(516):85-88.
Meyer-Lindenberg A., Domes G., Kirsch P., Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 2011, 19(12):524-538.
Miller G. The promise and perils of oxytocin. Science 2013, 339:267-269.
Legros J.J. Inhibitory effect of oxytocin on corticotrope function in humans: are vasopressin and oxytocin ying-yang neurohormones?. Psychoneuroendocrinology 2011, 26:649-655.
Okimoto N., Bosch O.J., Slattery D.A., Pflaum K., Matsushita H., Wei F.Y., et al. RGS2 mediates the anxiolytic effect of oxytocin. Brain Res 2012, 9(1453):26-33.
Ozsoy S., Esel E., Kula M. Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. Psychiatry Res 2009, 30(169):249-252.
Parker K.J., Kenna H.A., Zeitzer J.M., Keller J., Blasey C.M., Amico J.A., et al. Preliminary evidence that plasma oxytocin levels are elevated in major depression. Psychiatry Res 2010, 178:359-362.
Pincus D., Kose S., Arana A., Johnson K., Morgan P., Borckardt J., et al. Inverse effects of oxytocin on attributing mental activity to others in depressed and healthy subjects: a double-blind placebo controlled fMRI study. Front Psychiatr 2010, 1.
Scantamburlo G., Hansenne M., Fuchs S., Pitchot W., Maréchal P., Pequeux C., et al. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 2007, 32:407-410.
Scantamburlo G., Ansseau M., Geenen V., Legros J.J. Intranasal oxytocin as an adjunct to escitalopram in major depression. J Neuropsychiatry Clin Neurosci 2011, 23:2.
Spielberger C.D., Gorsuch R.L., Lushene R., Vagg P.R., Jacobs G.A. Manual for the state-trait anxiety inventory. Consulting psychologists' press 1983, Palo Alto, CA.
Turan T., Uysal C., Asdemir A., Kilic E. May oxytocin be a trait marker for bipolar disorder?. Psychoneuroendocrinology 2013, 38:2890-2896.
Uvnäs-Moberg K. Antistress pattern induced by oxytocin. News Physiol Sci 1998, 13:22-25.
van Ijzendoorn M., Bhandari R., van der Veen R., Grewen K., Bakermans-Kranenburg M.J. Elevated salivary levels of oxytocin persist more than seven hours after intranasal administration. Front Neurosci 2012, 6:174.
Zink C., Meyer-Lindenberg A. Human neuroimaging of ocytocin and vasopressin in social cognition. Horm Behav 2012, 61:400-409.